Fezo's a go (and it's Veozah now)
+ my favorite evidence-based supplement for hot flashes
This is your free weekend version of Hotflash inc. Previously I’ve shared my analysis of fezolinetant with paid subscribers, but I think it’s important that everyone gets it now that it will be hitting shelves in the US. The free roundup of hopefully helpful things will resume next week.
The US Food and Drug Administration approved Astellas Pharma’s non-hormonal drug for hot flashes this week. This means a 45mg daily dose of Veozah – which contains fezolinetant, which is what we’ve been calling it until this sudden new name appeared Friday – is the first such medication to make it to market. The Japanese drugmaker, which has also applied for regulatory review in EU, Switzerland and Australia, says Veozah could be in US pharmacies within weeks.
Previously the only non-hormonal, FDA-approved treatment for hot flashes was the anti-depressant paroxetine. If you want to read the FDA’s report for yourself, …
